Ratings Pfizer, Inc.

Equities

PFE

US7170811035

Real-time Estimate Cboe BZX Other stock markets 01:36:57 2023-09-29 pm EDT			5-day change	1st Jan Change
33.07 ^USD	+3.05%		+1.07%	-35.52%

06:58pm	Structure Therapeutics surges as early data from obesity pill tops expectations	RE
05:33am	Pfizer, BioNTech's XBB.1.5-adapted COVID-19 Shot Secures Canadian Nod	MT

Summary

The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company is in a robust financial situation considering its net cash and margin position.
The company is one of the best yield companies with high dividend expectations.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Pharmaceuticals

	1st Jan change	Capi. (M$)	Investor Rating	ESG Refinitiv
PFIZER, INC.	-35.52%	181 B $		A-
HEYU BIOLOGICAL TECHNOLOGY CORPORATION	+3757.14%	280 M $	-	-
HANALL BIOPHARMA CO., LTD.	+83.43%	1 225 M $		-
QURATIS INC.	0.00%	90 M $	-	-
TONGHUA GOLDEN-HORSE PHARMACEUTICAL INDUSTRY CO,LTD	+141.94%	1 688 M $	-	-
HA TAY PHARMACEUTICAL	+52.60%	59 M $	-	-
RECCE PHARMACEUTICALS LTD	-26.52%	56 M $	-	-
NEXT SCIENCE LIMITED	-36.50%	63 M $		-
JCR PHARMACEUTICALS CO., LTD.	-11.04%	1 150 M $		-
ANYGEN CO., LTD.	+83.27%	60 M $	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes